Abstract 496P
Background
Indication for treatment with osimertinib after first/second generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance depends on T790M mutation detected by re-biopsy. REMEDY trial consisting many cases using plasma biopsy revealed osimertinib introduction rate of approximately 25 percent in EGFR-mutant non-small cell lung cancer (NSCLC) patients pretreated with first/second generation EGFR-TKIs. The aim of study is to analyze the data on clinical practice of our hospital, where histological re-biopsy is actively carried out multiple times.
Methods
We retrospectively reviewed our electronic medical records of EGFR-mutant NSCLC patients to examine osimertinib introduction rate and associated outcomes.
Results
Among 95 patients with EGFR-mutant NSCLC, 73 patients received first/second generation EGFR-TKIs. Of 57 progressive disease patients, 50 patients (57/50: 87%) underwent re-biopsy. T790M was detected in 36 patients (36/50: 72%) and osimertinib was introduced in 35 patients (35/50: 70%). Among 36 patients harboring T790M mutation: histological re-biopsy was performed in 21 patients (21/36: 58%); cytology in 12 patients (12/36: 33%); blood biopsy in three patients (3/36: 8.3%). T790M was detected by first re-biopsy in 14 patients (14/36: 39%), and by second or subsequent re-biopsy 22 patients (22/36: 61%). The median overall survival (OS) in osimertinib induction patients was not reached (95% CI, 64.2-not reached) while in non- osimertinib patients median OS was 92.9 months (95% CI, 22.5-not reached) (p = 0.0173). Five year survival rates were 77% and 52%, respectively.
Conclusions
Higher osimertinib introduction rate was achieved by multiple repeated re-biopsy after first/second generation EGFR-TKIs, and its high introduction rate could contribute to better prognosis of EGFR-mutant NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kobe Minimally Invasive Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract